Results 101 to 110 of about 23,901 (228)
Absence of Interactions between Denosumab and Warfarin in Women with Osteoporosis
, 2018 The monoclonal antibody denosumab reduces bone resorption. Warfarin is an oral anticoagulant used in the prevention and treatment of thrombosis. To date, there have been no studies on the interaction between warfarin and denosumab. The aim of the present
Gianluca Sottilotta +4 more
core +1 more source
Periodontology 2000, EarlyView.Abstract Background/Aim Antiresorptive therapy represents a cornerstone in the management of osteoporosis and cancer‐related bone disease through suppression of osteoclast‐mediated bone resorption. As implant therapy becomes more common in aging populations, clinicians increasingly encounter patients receiving these medications, thus making their ...
Emilio A. Cafferata +2 more
wiley +1 more source
Case report: A case of ITP-like thrombocytopenia induced by denosumab
Frontiers in PharmacologyDenosumab has been widely utilized in the management of osteoporosis; however, thrombocytopenia as an adverse reaction associated with denosumab has been infrequently reported, and its underlying mechanism is not yet fully understood.
Shijing Chen, Xiahong Lin
doaj +1 more source
, 2017 Giant cell tumor (GCT) is a rare, usually benign but locally aggressive neoplasm. Recent studies suggest new approaches in light of the elucidation of molecular pathways in bone.
Mehmet Ali DevecI +3 more
core +1 more source
Transfusion, EarlyView.Abstract Background Cord blood‐derived red blood cell transfusions (CB‐RBCs) are being developed for extremely preterm neonates to preserve physiological fetal hemoglobin levels. We assessed how standard blood donor medication screening could be adapted for this novel donor population.
Jip H. van Daelen +12 more
wiley +1 more source
Denosumab and the Rebound Effect: Current Aspects of Osteoporosis Therapy (Review)
Безопасность и риск фармакотерапииINTRODUCTION. Osteoporosis is a leading cause of morbidity, disability, reduced quality of life, and premature mortality in the elderly population. Denosumab is a treatment for osteoporosis; however, denosumab discontinuation may cause a rebound effect ...
N. Yu. Velts +2 more
doaj +1 more source
Journal of Foot and Ankle Research, Volume 19, Issue 4, December 2026.ABSTRACT Background Hallux valgus is a frequent forefoot deformity in older adults and has been linked to impaired balance, gait dysfunction, and increased fall risk. However, its prevalence among patients with femoral neck fracture and its association with postoperative functional outcomes remain unclear. Methods This single‐center retrospective study
Kazuki Kanazawa +6 more
wiley +1 more source
Safety and efficacy of denosumab in the treatment of pulmonary metastatic giant cell tumor of bone
, 2018 Yi Luo, Fan Tang, Yitian Wang, Yong Zhou, Li Min, Wenli Zhang, Rui Shi, Hong Duan, Chongqi Tu Department of Orthopedics, West China Hospital, Sichuan University, Chengdu, China Background: Giant cell tumor (GCT) of bone is an intermittent and locally ...
Min L +8 more
core
Australasian Journal on Ageing, Volume 45, Issue 4, December 2026.ABSTRACT Objective Age‐related loss of lean mass is a hallmark of sarcopenia and a contributor to functional decline and morbidity in ageing populations. This study aimed to identify long‐term determinants of lean mass during ageing. Methods Data from 3033 participants (ages 20–96 years; 49% women) in the Geelong Osteoporosis Study were analysed using ...
Aminu Suleiman +6 more
wiley +1 more source